Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
Saved in:
| Title: | Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol. |
|---|---|
| Authors: | Spratt DE; Radiation Oncology, UH Seidman Cancer Center/Case Western Reserve University, Cleveland, OH 441062, USA., Dorff T; Medical Oncology, City of Hope, Duarte, CA 910103, USA., McKay RR; Medical Oncology, UC San Diego, La Jolla, CA 920374, USA., Lowentritt BH; Urology, Chesapeake Urology, Towson, MD 212045, USA., Fallick M; Myovant Sciences Inc., Brisbane, CA 940056, USA., Gatoulis SC; Pfizer, New York, NY 100177, USA., Flanders SC; Myovant Sciences Inc., Brisbane, CA & Sumitomo Pharma America Inc., Marlborough, MA 017528, USA., Ross AE; Urology, Northwestern Medicine, Chicago, IL 60611, USA. |
| Source: | Future oncology (London, England) [Future Oncol] 2024 Apr; Vol. 20 (12), pp. 727-738. Date of Electronic Publication: 2024 Mar 15. |
| Publication Type: | Journal Article; Clinical Trial Protocol |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
